We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CB:NYSEChubb Limited Analysis

Data as of 2026-09-10 - not real-time

$337.62

Latest Price

3/10Risk

Risk Level: Low

Executive Summary

At $337.62, Chubb Limited shows no decisive moving-average alignment, leaving the trend neutral. The last 30 days have lost 7.1%. RSI sits at 43.9, which reads as neutral, and MACD momentum is bearish. Recent trading has carved out support near $333.63 and resistance around $349.03.
On valuation the read is undervalued — earnings multiple of 11.9 versus a 16.2 sector average, below the peer group. The average analyst target implies 8.4% above today's level. Revenue is growing at 6.1% on a 18.1% profit margin. The 1.21% dividend yield looks covered by current payout levels.
Risk comes out at 3 of a possible 10, a low reading. With 30-day volatility of 18.0%, a beta of -0.34 and a maximum drawdown of 9.6%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 6/10 long-term conviction.

Top Market Events

Chubb Limited stock trades around its recent $343.Chubb Limited stock is trading close to $341 after a run of new institutional positions and a recentChubb Limited stock is holding just below its 52-week high, with Wall Street consensus targets still

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Trading above the 200-day average of 326.77
  • MACD momentum is negative
  • 30-day price change of -7.1%

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 11.9 versus sector average of 16.2
  • Trading above the 200-day average of 326.77
  • Analyst targets imply +8.4% versus the current price

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • P/E of 11.9 versus sector average of 16.2
  • Analyst targets imply +8.4% versus the current price
  • Profit margin of 18.1% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth6.10%
Profit Margin18.07%
P/E Ratio11.9
ROE14.82%
ROA3.36%
Debt/Equity30.94
P/B Ratio1.7
Op. Cash Flow$15.4B
Free Cash Flow$10.5B
Industry P/E16.2

Technical Analysis

TrendNeutral
RSI43.9
Support$333.63
Resistance$349.03
MA 20$341.71
MA 50$347.72
MA 200$326.77
MACDBearish
VolumeDecreasing
Fear & Greed Index92.02

Valuation

Fair Value$400.19
Target Price$366.13
Upside/Downside8.44%
GradeUndervalued
TypeBlend
Dividend Yield1.21%

Risk Assessment

Beta-0.34
Volatility17.95%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.